Search research articles
Contact Us
Filters
Showing results (161-170 of 272) with videos related to
Page
of 28
Sort By:
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
JCO Precision Oncology
|
January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
Niamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
The International Journal of Cardiovascular Imaging
|
June 14, 2024
Intravascular imaging-guided percutaneous coronary intervention for heavily calcified coronary lesions: a systematic review and meta-analysis
Doosup Shin, David Hong, Mandeep Singh, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
ACS Infectious Diseases
|
December 22, 2020
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew V Stachulski, Joshua Taujanskas, Sophie L Pate, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
JACC. Cardiovascular Interventions
|
March 27, 2024
Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary Stenosis
Seung Hun Lee, Ki Hong Choi, David Hong, et al.
Page
of 28
Search research articles
Search
Showing results (161-170 of 272) with videos related to
Sort By:
Page
of 28
Investigational New Drugs
|
April 24, 2015
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy
Heloisa Veasey Rodrigues, Danxia Ke, JoAnn Lim, et al.
JCO Precision Oncology
|
January 5, 2023
<i>HRAS</i> Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
Niamh Coleman, Kathrina L Marcelo, Julia F Hopkins, et al.
The International Journal of Cardiovascular Imaging
|
June 14, 2024
Intravascular imaging-guided percutaneous coronary intervention for heavily calcified coronary lesions: a systematic review and meta-analysis
Doosup Shin, David Hong, Mandeep Singh, et al.
Cancer Immunology Research
|
September 5, 2014
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, Hendrick Soh, et al.
ACS Infectious Diseases
|
December 22, 2020
Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew V Stachulski, Joshua Taujanskas, Sophie L Pate, et al.
Oncology
|
June 24, 2019
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors
David Hong, Drew Rasco, Michael Veeder, et al.
Oncotarget
|
April 22, 2017
Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer
Zhijie Wang, Sarina Piha-Paul, Filip Janku, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 6, 2016
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong, Jeffrey Infante, Filip Janku, et al.
Molecular Cancer Therapeutics
|
September 26, 2014
Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents
Prasanth Ganesan, Stacy Moulder, J Jack Lee, et al.
JACC. Cardiovascular Interventions
|
March 27, 2024
Prognostic Implications of Microvascular Resistance Reserve in Symptomatic Patients With Intermediate Coronary Stenosis
Seung Hun Lee, Ki Hong Choi, David Hong, et al.
Page
of 28